Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. A standard approach and the results of innovative studies

Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. A standard approach and the results of innovative studies

Show other versions (1)

Prostate cancer (PC) is one of the most burning problems of modern urologic oncology. Hormonal therapy (HT) using medical castrationremains a basic therapy for metastatic PC. HT with a novel class of luteinizing hormone-releasing hormone (LHRH) receptor antagonists isa promising and effective castra...

Full description

Bibliographic Details
Main Authors:	K. M. Nyushko, B. Ya. Alekseev, A. S. Kalpinsky, A. D. Kaprin
Format:	Article
Language:	Russian
Published:	ABV-press 2014-12-01
Series:	Onkourologiâ
Subjects:	prostate cancer luteinizing hormone-releasing hormone analogues and antagonists degarelix castration-refractoriness cardiovascular disease cardiovascular risk
Online Access:	https://oncourology.abvpress.ru/oncur/article/view/399

Similar Items

Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. A standard approach and the results of innovative studies
by: K. M. Nyushko, et al.
Published: (2014-12-01)

HORMONE THERAPY WITH USAGE OF AGONISTS AND ANTAGONISTS OF LUTEINIZING HORMONE RELEASING HORMONE IN PATIENTS WITH PROSTATE CANCER
by: K. M. Nyushko, et al.
Published: (2015-01-01)

ANDROGEN DEPRIVATION THERAPY WITH LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONISTS FOR PROSTATE CANCER: BEST DISEASE CONTROL WITH A LOWER RISK OF SIDE EFFECTS. RESULTS OF ANALYSIS OF 6 COMPARATIVE RANDOMIZED PHASE III TRIALS OF DEGARELIX AND LUTEINIZIN
by: A. S. Markova, et al.
Published: (2014-07-01)

ANDROGEN DEPRIVATION THERAPY WITH LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONISTS FOR PROSTATE CANCER: BEST DISEASE CONTROL WITH A LOWER RISK OF SIDE EFFECTS. RESULTS OF ANALYSIS OF 6 COMPARATIVE RANDOMIZED PHASE III TRIALS OF DEGARELIX AND LUTEINIZIN
by: A. S. Markova, et al.
Published: (2014-07-01)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
by: Jumpei Asakawa, et al.
Published: (2018-07-01)

Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer
by: B. Ya. Alexeev, et al.
Published: (2018-11-01)

EFFICIENCY OF HORMONE THERAPY WITH LEIPRORELIN (LUCRIN DEPOT®) IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

EFFICIENCY OF HORMONE THERAPY WITH LEIPRORELIN (LUCRIN DEPOT®) IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
by: Liu YF, et al.
Published: (2021-02-01)

INTERMITTENT HORMONE THERAPY IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseyev, et al.
Published: (2014-07-01)

INTERMITTENT HORMONE THERAPY IN PATIENTS WITH PROSTATE CANCER
by: B. Ya. Alekseyev, et al.
Published: (2014-07-01)

Luteinizing hormone changes in gonadotropin-releasing hormone antagonist protocol in in vitro fertilization cycles: A cross-sectional study
by: Batool Hosein Rashidi, et al.
Published: (2019-03-01)

THE USE OF MODERN ANALOGUES OF LUTEINIZING HORMONE RELEASING HORMONE IN THE HORMONAL THERAPY IN PATIENTS WITH PROSTATE CANCER
by: E. Yu. Safronova, et al.
Published: (2017-06-01)

Diminished ovarian reserve predisposes to premature luteinizing hormone surges in gonadotropin-releasing hormone antagonist cycles in In vitro fertilization
by: Puneet Kaur Kochhar, et al.
Published: (2020-01-01)

A ROLE OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

A ROLE OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER
by: B. Ya. Alekseev, et al.
Published: (2014-07-01)

Is there a Need for Luteinizing Hormone (LH) Estimation in Patients Undergoing Ovarian Stimulation with Gonadotropin-Releasing Hormone (GnRH) Antagonists and Recombinant Follicle-Stimulating Hormone (rFSH)?
by: Amar Ramachandran, et al.
Published: (2014-01-01)

Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists
by: V. B. Matveev, et al.
Published: (2021-07-01)

Luteinizing Hormone Releasing Hormone/Galactose Core/Lipopeptide
by: Pavla Simerska, et al.
Published: (2015-12-01)

Do basal luteinizing hormone and luteinizing hormone/follicle-stimulating hormone ratio have significance in prognosticating the outcome of In vitro fertilization cycles in polycystic ovary syndrome?
by: Neeta Singh, et al.
Published: (2021-01-01)

HORMONAL THERAPY WITH LEUPRORELIN (LUCRIN-DEPOT®) IN PATIENTS WITH PROSTATE CANCER
by: I. G. Rusakov, et al.
Published: (2014-08-01)

HORMONAL THERAPY WITH LEUPRORELIN (LUCRIN-DEPOT®) IN PATIENTS WITH PROSTATE CANCER
by: I. G. Rusakov, et al.
Published: (2014-08-01)

Pharmacoeconomic study of the degarelix drug use for treatment of hormone-dependent prostate cancer compared to gonadotropin-releasing hormone analogs
by: A. G. Tolkushin, et al.
Published: (2018-04-01)

Attempts to induce puberty in beef heifers with luteinizing hormone-releasing hormone
by: Skaggs, Chris L.
Published: (2015)

Hormone naïve prostate cancer: predicting and maximizing response intervals
by: Judd W Moul
Published: (2015-01-01)

Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels
by: Liang-Hsuan Chen, et al.
Published: (2021-07-01)

Diferelin® as an effective chemical castration agent for patients with prostate cancer
by: K. M. Nyushko, et al.
Published: (2021-02-01)

Luteinizing Hormone Levels Relate to the Unfavorable Pathology of Prostate Cancer
by: Se Young Choi, et al.
Published: (2020-04-01)

Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines
by: Sipos E, et al.
Published: (2018-02-01)

Effects of Luteinizing Hormone Supplementation on Ovarian Response and Assisted Reproductive Technology Outcomes in Antagonist In vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: A Meta-analysis
by: Lei Chen, et al.
Published: (2019-01-01)

Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use
by: Bruno Lopes Cançado, et al.

Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
by: Zhang L, et al.
Published: (2018-02-01)

DEGARELIX ROLE AND PLACE IN THE COMBINED TREATMENT OF PATIENTS WITH PROSTATE CANCER IN COMBINATION WITH CONCURRENT RADIOTHERAPY
by: A. Y. Pavlov, et al.
Published: (2016-02-01)

Degarelix and its therapeutic potential in the treatment of prostate cancer
by: Christian Doehn, et al.
Published: (2009-05-01)

ROLE OF DEGARELIX (FIRMAGON) IN THE TREATMENT OF DISSEMINATED PROSTATE CANCER: CAN THE QUALITY OF CASTRATION THERAPY BE IMPROVED?
by: V. B. Matveev, et al.
Published: (2014-07-01)

ROLE OF DEGARELIX (FIRMAGON) IN THE TREATMENT OF DISSEMINATED PROSTATE CANCER: CAN THE QUALITY OF CASTRATION THERAPY BE IMPROVED?
by: V. B. Matveev, et al.
Published: (2014-07-01)

Hormonal modulation of Leydig cell membrane luteinizing hormone receptors /
by: Hussein, Mohamed Osman
Published: (1986)

Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome
by: Liu Nana, et al.
Published: (2012-04-01)

Structure and function of gonadotropin-releasing hormone in the Thai catfish, Clarias macrocephalus
by: Ngamvongchon, Somsri
Published: (2018)

Effect of Ghrelin Antagonist on Serum Testosterone and Luteinizing Hormone in Obese Type 2 Diabetic Mice
by: Lubna Siddique
Published: (2014-06-01)